

Special Issue

Products from Marine Actinomycetes

Message from the Guest Editor

The marine environment is one of the most intensively explored sources of microbial diversity and in recent years new taxonomic groups of marine actinomycetes have been described with rich metabolic capacities. The metabolic diversity within marine actinobacteria is supported by the exponentially growing genome sequence information available from public databases. The evidence of a broad distribution of indigenous actinomycetes in the sea is now overwhelming as well as the presence of novel strains that have not yet been cultivated. Current technology advances and available omics platforms supporting the development of merging disciplines in synthetic biology, chemistry and microbiology are driving the exploration of the broad microbial and chemical diversities in the marine environment. All together they are paving the way to enable the discovery of novel bioactive compounds with potential applications in a broad range of therapeutic and biotechnology areas. This SI aims to cover all most recent advances in the field of marine actinomycetes natural products research and how these approaches are contributing to define novel trends in marine natural products drug discovery.


Guest Editor

Dr. Olga Genilloud

Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Parque Tecnológico Ciencias de la Salud, Avenida del Conocimiento 34, Granada, Spain

Deadline for manuscript submissions

closed (3 July 2020)



Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.6
Indexed in PubMed



mdpi.com/si/29820

Marine Drugs
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)





Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.6
Indexed in PubMed



[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))